6 results on '"Kaldoun Kerrou"'
Search Results
2. Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
- Author
-
Jean-Yves Pierga, Alina Berriolo-Riedinger, Thierry Petit, Laurent Arnould, David Coeffic, Abdennour Ferhat, Gilles Paintaud, Jean-Briac Prevost, Pierre-Francois Dupre, Fanny Le Du, Thomas Bachelot, Marie-Pierre Chauvet, Jean-Marc Ferrero, Gilles Thibault, Kaldoun Kerrou, Philippe Gabelle, Catherine Barbe, Julien Dupin, Bruno Coudert, Marie-Ange Mouret-Reynier, Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Institut Curie [Paris], Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Centre Paul Strauss, CRLCC Paul Strauss, Centre Eugène Marquis (CRLCC), Hôpital Morvan - CHRU de Brest (CHU - BREST ), Centre Léon Bérard [Lyon], Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Roche France, Département d'information médicale [Centre Georges-François Leclerc] (DIM), UNICANCER-UNICANCER, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Université de Lille-UNICANCER
- Subjects
Oncology ,medicine.medical_specialty ,Positron emission tomography ,Early pet assessment ,Bevacizumab ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,01 natural sciences ,Group B ,03 medical and health sciences ,Her-2 positive breast cancer ,0302 clinical medicine ,Breast cancer ,Trastuzumab ,Internal medicine ,medicine ,Adjuvant therapy ,030212 general & internal medicine ,0101 mathematics ,Adverse effect ,Long-term follow-up ,Neoadjuvant therapy ,lcsh:R5-920 ,business.industry ,010102 general mathematics ,General Medicine ,medicine.disease ,3. Good health ,Docetaxel ,pathological complete response ,Δsuvmax ,Neoadjuvant ,lcsh:Medicine (General) ,business ,Research Paper ,medicine.drug - Abstract
Background: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improved pathological complete response (pCR) rates (43.8% vs 24.0%). We investigated long-term study outcomes. Methods: Patients were treated in three groups. All patients initially received two cycles of standard neoadjuvant therapy with [¹⁸F]-FDG PET conducted before each cycle. Those with ≥70% change in the maximum standardised uptake value (∆SUVmax) received four further cycles of standard neoadjuvant therapy (PET responders). PET-predicted poor-responders (∆SUVmax
- Published
- 2020
3. Long-Term Outcomes in Patients with PET-Predicted Poor-Responsive HER2-Positive Breast Cancer Treated with Neoadjuvant Bevacizumab Added to Trastuzumab and Docetaxel: 5-Year Follow-Up of the Randomised AVATAXHER Study
- Author
-
Pierre-Francois Dupre, Marie-Pierre Chauvet, Jean Marc Ferrero, David Coeffic, Jean-Briac Prevost, Thomas Bachelot, Thierry Petit, Alina Berriolo-Riedinger, Catherine Barbe, Julien Dupin, Gilles Paintaud, Kaldoun Kerrou, Philippe Gabelle, Laurent Arnould, Jean-Yves Pierga, Fanny Le Du, Marie-Ange Mouret-Reynier, Bruno Coudert, and Abdennour Ferhat
- Subjects
medicine.medical_specialty ,Bevacizumab ,business.industry ,medicine.medical_treatment ,medicine.disease ,Breast cancer ,Docetaxel ,Trastuzumab ,Internal medicine ,medicine ,Hormonal therapy ,Cumulative incidence ,business ,Adverse effect ,Neoadjuvant therapy ,medicine.drug - Abstract
Background: The open-label, randomised Phase 2 AVATAXHER study demonstrated that early PET assessment identified patients with HER-2 positive breast cancer who responded poorly to standard neoadjuvant therapy (docetaxel plus trastuzumab). Adding bevacizumab to neoadjuvant therapy in PET-predicted poor-responders improved pathological complete response (pCR) rates (from 24·0% to 43·8%). We investigated whether the improved pCR rate translated into improved long-term outcomes. Methods: Patients were treated in three groups. All patients initially received two cycles of standard neoadjuvant therapy with [¹⁸F]-FDG PET conducted before each cycle. Those with a change in the maximum standardised uptake value (∆SUVmax) ≥70% received four further cycles of standard neoadjuvant therapy (PET responder group). PET-predicted poor-responders (∆SUVmax
- Published
- 2019
4. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
- Author
-
Alina Berriolo-Riedinger, Thomas Bachelot, David Coeffic, Jean-Briac Prevost, Juana Hernandez, Philippe Gabelle, Jean-Yves Pierga, Pierre-Francois Dupre, Laurent Arnould, Gilles Thibault, Kaldoun Kerrou, Philippe Bougnoux, Thierry Petit, Jean-Marc Ferrero, Gilles Paintaud, Bruno Coudert, Sylvia Giard, Marie-Ange Mouret-Reynier, Pierre Kerbrat, and Mathieu Coudert
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Bevacizumab ,Receptor, ErbB-2 ,medicine.medical_treatment ,Population ,Breast Neoplasms ,Docetaxel ,Antibodies, Monoclonal, Humanized ,Breast cancer ,Fluorodeoxyglucose F18 ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Clinical endpoint ,Humans ,education ,Survival rate ,Neoadjuvant therapy ,Neoplasm Staging ,education.field_of_study ,business.industry ,Carcinoma, Ductal, Breast ,Middle Aged ,Trastuzumab ,medicine.disease ,Prognosis ,Combined Modality Therapy ,Neoadjuvant Therapy ,Surgery ,Survival Rate ,Chemotherapy, Adjuvant ,Lymphatic Metastasis ,Positron-Emission Tomography ,Female ,Taxoids ,Neoplasm Grading ,Radiopharmaceuticals ,business ,Febrile neutropenia ,medicine.drug ,Follow-Up Studies - Abstract
Summary Background An effective and well tolerated treatment is needed for patients with early HER2-positive breast cancer who do not achieve a pathological complete response after neoadjuvant therapy. The AVATAXHER trial aimed to predict pathological complete response early with the use of PET and to investigate whether the addition of bevacizumab could improve the proportion of patients achieving a pathological complete response in patients unlikely to respond to treatment. Methods AVATAXHER was a randomised, open-label, non-comparative, multicentre phase 2 study that enrolled women (≥18 years of age) with early-stage HER2-positive breast cancer from 26 oncology centres in France. Patients initially received two cycles of neoadjuvant docetaxel (100 mg/m 2 intravenously every 3 weeks) plus trastuzumab (8 mg/kg intravenously every 3 weeks then 6 mg/kg intravenously every 3 weeks for the second course). Before the first and second cycles, [ 18 F]-fluorodeoxyglucose (FDG) PET was done and the change in standardised uptake value was used to predict pathological complete response in each patient. Patients who were predicted to be responders on PET continued to receive standard therapy. Predicted non-responders were randomly assigned (2:1) to receive four cycles of docetaxel (100 mg/m 2 intravenously every 3 weeks) and trastuzumab (6 mg/kg intravenously every 3 weeks) plus bevacizumab (15 mg/kg intravenously every 3 weeks; group A) or continue on docetaxel plus trastuzumab alone (group B). Randomisation was open label and was done by an adaptive minimisation method. Although investigators and patients were aware of group assignment, the anatomo-pathologist in charge of centralised review of surgical samples and lymph nodes was masked to treatment assignment. The primary endpoint was centrally assessed pathological complete response according to the Chevallier classification. Efficacy analyses were done in the intention-to-treat population. Safety analyses in this Article were done on all patients who received at least one dose of treatment starting from cycle 3. Survival outcomes are not yet mature. This study is registered with ClinicalTrials.gov (NCT01142778) and EUDRACT (2009-013410-26). Findings Between May 19, 2010, and Oct 1, 2012, 152 patients were recruited for the study. Ten patients were subsequently excluded, leaving 142 patients in the intention-to-treat population. Of these 142 patients, 69 were predicted by [ 18 F]-FDG PET to be treatment responders after two cycles of treatment. The 73 predicted non-responders were randomly assigned to group A (n=48) and group B (n=25). Pathological complete responses were noted in 37 (53·6%, 95% CI 41·2–65·7) of the PET responders, 21 (43·8%, 29·5–58·8) of those in group A, and six (24·0%, 9·4–45·1) of those in group B. Incidences of grade 3–4 adverse events were similar in all three groups. The most common grade 3–4 adverse events were neutropenia (four in PET responders, five in group A, and three in group B), febrile neutropenia (one, three, and one, respectively), and myalgia (four, none, and one, respectively). Overall, 24 serious adverse events were reported in 15 patients (PET responders: nine events in four [6%] of 67 patients; group A: 14 events in ten [21%] of 47 patients; group B: one event in one [4%] of 25 patients). No deaths occurred during the study. Interpretation In patients with HER2-positive breast cancer, early PET assessment can help to identify non-responders to neoadjuvant docetaxel plus trastuzumab therapy. In these patients, the addition of bevacizumab can increase the proportion of patients achieving a pathological complete response. This potential new role for PET and the activity of bevacizumab in this setting need to be confirmed in larger phase 3 trials. Funding Roche France.
- Published
- 2014
5. Place of a hand-held gamma camera (POCI) in the breast cancer sentinel node biopsy
- Author
-
Kaldoun Kerrou, Serge Uzan, Emmanuel Barranger, Yves Charon, Stephanie Pitre, and Marie-Alix Duval
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Sentinel Lymph Node Biopsy ,Hand held ,Breast Neoplasms ,General Medicine ,Equipment Design ,Sentinel node ,medicine.disease ,law.invention ,Breast cancer ,law ,Lymphatic Metastasis ,Biopsy ,medicine ,Image Processing, Computer-Assisted ,Humans ,Surgery ,Female ,Gamma Cameras ,Radiology ,business ,Gamma camera - Published
- 2007
6. [Place of hand-held gamma camera (POCI) in sentinel node biopsy]
- Author
-
Emmanuel, Barranger, Kaldoun, Kerrou, Stéphanie, Pitre, Marie-Alix, Duval, Rienert, Siebert, Yves, Charon, and Serge, Uzan
- Subjects
Sentinel Lymph Node Biopsy ,Neoplasms ,Image Processing, Computer-Assisted ,Humans ,Radionuclide Imaging - Abstract
The main interest in the sentinel node (SN) detection concept has led to the development of several prototypes of hand held gamma cameras. After the first successful clinical trials with intra-operative imaging probes, the time has come to evaluate the potential benefits of these devices. The objective of this review was to show the potential interest of a hand-held camera POCI to perform a lymphoscintigraphy in order to precisely localize SNs in patients with breast cancer.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.